Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Verrica Pharmaceuticals (VRCA)

June 23, 2026 6:53 AM EDT Send to a Friend
H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $12.00 price target on Verrica Pharmaceuticals (NASDAQ: VRCA).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login